Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00872_DB01394 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00872_DB01394 label "DDI between Conivaptan and Colchicine - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. In patients with normal renal and hepatic function, reduce colchicine dose (for gout flares: to 0.6 mg x 1 dose, followed by 0.3 mg 1 hour later, with next dose no sooner than 3 days later; for gout flare prophylaxis: if target dose would otherwise be 0.6 mg daily, change to 0.3 mg every other day, and if target dose would otherwise be 0.6 mg twice daily, change to 0.3 mg daily; for Familial Mediterranean Fever: to no more than 0.6 mg/day) when using in combination with a strong CYP3A4 inhibitor such as clarithromycin or ritonavir. Increase monitoring for colchicine-related toxicity when using such combinations. Colchicine use is contraindicated in patients with impaired renal and/or hepatic function who are also receiving a strong CYP3A4 inhibitor. [drugbank_resource:DB00872_DB01394]" assertion.
- drugbank_resource:DB00872_DB01394 identifier "drugbank_resource:DB00872_DB01394" assertion.
- drugbank_resource:DB00872_DB01394 title "DDI between Conivaptan and Colchicine - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. In patients with normal renal and hepatic function, reduce colchicine dose (for gout flares: to 0.6 mg x 1 dose, followed by 0.3 mg 1 hour later, with next dose no sooner than 3 days later; for gout flare prophylaxis: if target dose would otherwise be 0.6 mg daily, change to 0.3 mg every other day, and if target dose would otherwise be 0.6 mg twice daily, change to 0.3 mg daily; for Familial Mediterranean Fever: to no more than 0.6 mg/day) when using in combination with a strong CYP3A4 inhibitor such as clarithromycin or ritonavir. Increase monitoring for colchicine-related toxicity when using such combinations. Colchicine use is contraindicated in patients with impaired renal and/or hepatic function who are also receiving a strong CYP3A4 inhibitor." assertion.
- drugbank:DB01394 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00872_DB01394 assertion.
- drugbank:DB00872 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00872_DB01394 assertion.